Trending...
- Bruce C. Barnes Joins Summit's Board of Advisors
- New Article by Roy J. Meidinger – Examines Hidden Hidden Healthcare Kickbacks
- Crypto Betting Odds 2025: Bookmakers Review Analyzes Market Predictions and Year-End Price Lines
Webcast scheduled for Monday, July 22 at 8:00 a.m. Eastern Time
CARLSBAD, Calif., July 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, July 22nd at 8:00 a.m. Eastern Time to discuss results from the Phase 1/2a HALOS study of ION582 for the treatment of people with Angelman syndrome. Results from the HALOS study will also be presented on Wednesday, July 24 at the 2024 Angelman Syndrome Foundation (ASF) Family Conference and Research Symposium in Sandusky, Ohio.
The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.
More on Ohio Pen
Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. – [email protected] – 760-603-2331
Ionis Pharmaceuticals Media Contact:
Hayley Soffer – [email protected] – 760-603-4679
SOURCE Ionis Pharmaceuticals, Inc.
CARLSBAD, Calif., July 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, July 22nd at 8:00 a.m. Eastern Time to discuss results from the Phase 1/2a HALOS study of ION582 for the treatment of people with Angelman syndrome. Results from the HALOS study will also be presented on Wednesday, July 24 at the 2024 Angelman Syndrome Foundation (ASF) Family Conference and Research Symposium in Sandusky, Ohio.
The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter) and LinkedIn.
More on Ohio Pen
- Colorado Families Turn to Private Autopsies for Peace of Mind
- $5.4 Million Growth Acceleration, Fleet Expansion and $1.485 Million Strategic Financing: Multi Ways Holdings (N Y S E: MWG) $MWG
- Delta Capital Group Expands Business Funding Terms Up to 24 Months
- Hip-HopVibe.com Launches HHV Media Network in Partnership with The Publisher Desk
- CCHR: Misinformation Clouds Debate on Psychiatric Drug Toxicology Transparency
Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. – [email protected] – 760-603-2331
Ionis Pharmaceuticals Media Contact:
Hayley Soffer – [email protected] – 760-603-4679
SOURCE Ionis Pharmaceuticals, Inc.
Filed Under: Business
0 Comments
Latest on Ohio Pen
- Generation Own: Why Young Americans Are Skipping Corporate Careers to Buy Million-Dollar Businesses
- Dongsheng's Titanium Recycling Business Enters Aerospace Sector by 2025
- Crowdfunding Campaign Tips Off for 'NAWFSIDE' Short Film Highlighting Pressure in Youth Sports
- Icarus IFE Systems Launches the Icarus One Portable Inflight Entertainment System — The World's Most Advanced Offline AI-Driven IFE Platform
- AEI Stands Firmly with Pakistani Aircraft Engineers facing retaliation for reporting safety concerns
- Literary fiction novel- 'Skylark' wins Bronze Medal
- Kaltra unveils reversible microchannel coils – engineered for modern heat pumps
- Phinge Announces Proposal to Combat Billions in Government Waste, Fraud, and Abuse with Proactive, Hardware-Verified Netverse App-Less Platform
- Taboo: The Lost Codes of Men — A Bold New Book Confronting the Crisis of Modern Manhood
- Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
- 'Wild Hermit Wellness' Has Achieved Bestseller Status in Just 2 Months Since Launch Of Organic Skincare Line
- Easton & Easton, LLP Sues The Dwelling Place Anaheim and Vineyard USA for Failing to Protect Minor from Church Leaders' Sexual Abuse
- Lokal Media House Earns ServiceTitan Certified Marketer Status
- Wall Street's New Obsession? Tradewinds Aims to Revolutionize the $8B Gentlemen's Club Industry with National Peppermint Hippo™ Strategy $TRWD
- Poised for Major Growth with Strategic Military Orders, Global Expansion, and Groundbreaking Underground Mining Initiative $RMXI
- XRP fever is coming again, WOA Crypto helps the new trend and earns tens of thousands of dollars a day
- Inflation Rebounds Under Tariff Shadow: Wall Street Veteran Kieran Winterbourne Says Macro Signals Matter More Than Market Sentiment
- Mensa Foundation's New Science Program Encourages Hands-On Discovery
- Golden Paper Introduces TAD Hand Towel Technology, Ushering in a New Era of Premium Tissue Quality
- ReedSmith® Creates Founder-Investor Connections at The Investor Dating Game™ by Tech Coast Venture Network During LA Tech Week